Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

Background. To determine the maximum tolerable infusion rate of rituximab, and investigate the safety and feasibility of rapid infusion of rituximab for patients with CD20 positive B-cell lymphomas (CD20+NHL). Patients and Methods. 18 patients with CD20+NHL were registered. This study had six cohort...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yokoyama, Masahiro, Terui, Yasuhito, Takeuchi, Kengo, Nara, Eriko, Nakano, Kenji, Ueda, Kyoko, Nishimura, Noriko, Mishima, Yuko, Sakajiri, Sakura, Tsuyama, Naoko, Ozawa, Keiya, Hatake, Kiyohiko
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3649348/
https://ncbi.nlm.nih.gov/pubmed/23691364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2013/863909
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados